Connect with us

Published

on

This story also ran on NBC News. It can be republished for free.

When Phyllisa Deroze was told she had diabetes in a Fayetteville, North Carolina, emergency department years ago, she was handed pamphlets with information on two types of the disease. One had pictures of children on it, she recalled, while the other had pictures of seniors.

Deroze, a 31-year-old English professor at the time, was confused about which images were meant to depict her. Initially, she was diagnosed with Type 2 diabetes, as shown on the pamphlet with older adults. It would be eight years before she learned she had a different form of diabetes one that didnt fit neatly on either pamphlet.

The condition is often called latent autoimmune diabetes of adults, or LADA for short. Patients with it can be misdiagnosed with Type 2 diabetes and spend months or years trying to manage the wrong condition. As many as 10% of patients diagnosed with Type 2 diabetes might actually have LADA, said Jason Gaglia, an endocrinologist at the Joslin Diabetes Center in Boston.

Deroze and three other LADA patients who spoke with KFF Health News, all Black women, are among those who were initially misdiagnosed. Without the correct diagnosis which can be confirmed through blood tests they described being denied the medicines, technology, and tests to properly treat their diabetes. Three of them wonder if their race played a role. Phyllisa Deroze first asked to have her blood tested for antibodies associated with Type 1 diabetes six years after being diagnosed with Type 2 diabetes. Two years later, after two endocrinologists denied her requests, she persuaded her gynecologist to run a test. The results came back positive, showing she indeed had diabetes, but not Type 2.(Kathryn Pitts)

That does seem to happen more frequently for African American patients and for other minoritized groups, said Rochelle Naylor, a pediatric endocrinologist at the University of Chicago who researches atypical forms of diabetes. Doctors, like any other person walking this planet, we all have implicit biases that impact our patient experiences and our patient care delivery.

Black patients have long struggled with bias across the U.S. health care system. In a recent KFF survey, for example, 55% of Black adults said they believed they needed to be careful at least some of the time about their appearances to be treated fairly during medical visits. Hospital software used to treat patients has been investigated for discrimination. Even a common test used to manage diabetes can underestimate blood sugar levels for patients who have sickle cell trait, which is present in nearly 1 in 10 African Americans.

LADA ostensibly has nothing to do with race, but misconceptions about race, weight, and age can all lead doctors to misdiagnose LADA patients with Type 2 diabetes, said Kathleen Wyne, an endocrinologist who leads the adult Type 1 diabetes program at Ohio State University. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

Type 2 diabetes develops in people, often over age 45, whose bodies cannot properly regulate their blood sugar levels. Type 2 accounts for at least 90% of diabetes cases in the U.S. and has a high prevalence among African Americans, Native Americans, and Hispanic populations. It can often be managed with lifestyle changes and oral medications.

LADA is more akin to, or even thought to be another form of, Type 1 diabetes, an autoimmune condition once dubbed juvenile diabetes because it was most often diagnosed in children. Type 1 occurs when the body attacks its cells that produce insulin the naturally occurring hormone that regulates blood sugar by helping turn food into energy. Without insulin, humans cant survive.

LADA is difficult to diagnose because it progresses slowly, Gaglia said. Typical LADA patients are over 30 and dont require injectable insulin for at least six months after diagnosis. But, like Type 1 patients, most will eventually depend on injections of pharmaceutical insulin for the rest of their lives. That delay can lead physicians to believe their patients have Type 2 diabetes even as treatment becomes less effective.

If you have someone who comes into your office who is obese and/or overweight and may have a family history of Type 2 diabetes if youre a betting person, you bet on them having Type 2 diabetes, Gaglia said. But thats the thing with LADA: It unmasks itself over time. In the health care system, it’s really hard to vocalize your needs when you are a woman of color because you come off as aggressive, or you come off as a know-it-all, or you come off as disrespectful, Mila Clarke says. My intuition was right this whole time, but nobody believed me. (Brandon Thibodeaux for KFF Health News)

Mila Clarke, who lives in Houston, finally saw an endocrinologist in November 2020, more than four years after being diagnosed with Type 2 diabetes. During that visit, she recounted her struggles to manage her blood sugar despite taking oral medications and making significant changes to her diet and exercise regimens.

What you just explained to me, I believe, is a classic case of LADA, Clarke recalled being told. Has anybody ever tested you for Type 1 antibodies?

Because both Type 1 diabetes and LADA are autoimmune conditions, patients will have antibodies that Type 2 patients typically dont. But, as Clarke recounted, getting tested for those various antibodies isnt always easy.

Clarke, now 34, had leaned into her Type 2 diagnosis when she received it in 2016 at age 26. She started a blog with nutrition and lifestyle tips for people with diabetes called Hangry Woman, and garnered tens of thousands of followers on Instagram. Clarke said she wanted to fight the stigma around Type 2 diabetes, which stereotypes often associate with being overweight.

Some of the harshest comments that I had gotten were from people with Type 1 who were like, We’re not the same. I didn’t cause this. I didn’t do this to myself, Clarke said. Well, neither did I.

Clarke also felt her initial doctor thought she just wasnt working hard enough.

When she learned about continuous glucose monitors, wearable electronic devices that allow patients to track their blood sugar around the clock, she asked her primary care doctor to prescribe one. The monitors are recommended for patients with Type 1 and, more recently, some with Type 2. He flat-out told me, No. Its going to be too much information, too much data for you, she recalled.

Clarke switched to a different primary care doctor who she felt listened better and who prescribed a continuous glucose monitor. (Clarke later became a paid ambassador for the company that manufactures her device.) The new doctor eventually referred Clarke to the endocrinologist who asked if shed been tested for antibodies. The test came back positive. Clarke had LADA.

In the health care system, it’s really hard to vocalize your needs when you are a woman of color because you come off as aggressive, or you come off as a know-it-all, or you come off as disrespectful, Clarke said. My intuition was right this whole time, but nobody believed me. Mila Clarke inserts a syringe into a vial of insulin, which she uses to treat her diabetes.(Brandon Thibodeaux for KFF Health News)

Immediately, Clarke noticed an eye-opening difference in how she was treated. She started insulin injections and was referred to a dietitian and a diabetes educator. She wondered: Why wasnt it easier to get tested for antibodies?

Those tests are imperfect and can have false positives, said Gaglia of the Joslin center. Still, Ohio States Wyne argued that every diabetes patient should be tested for at least the most common antibody associated with Type 1.

Aren’t you saving lives if you’re identifying the Type 1 before they come in with DKA and die? Wyne asked, referring to diabetic ketoacidosis, a serious complication of diabetes most commonly associated with Type 1.

Deroze started asing her doctor for antibodies tests in 2017 after reading about a Type 2 bloggers experience being newly diagnosed with LADA.

Her endocrinologist denied her requests. She thinks the doctor thought it was impossible for her to have an autoimmune form of diabetes because of her race and weight. She sought a second opinion from a different endocrinologist, who also refused to test her.

I just felt unseen, Deroze said.

After a bout with diabetic ketoacidosis in 2019, Deroze finally persuaded her gynecologist to test her for antibodies. The results came back positive. One of the endocrinologists apologetically prescribed insulin and, later, an insulin pump, another ubiquitous piece of technology for people with Type 1.

And for the first time, she encountered the words diabetes is not your fault while reading about Type 1 diabetes. It felt like society was caring for her in a way it hadnt when she was misdiagnosed with Type 2. Thats troubling, she said, and so is how long it took to get what she needed.

My PhD didnt save me, said Deroze, who now lives in the Miami area. You just see the color of my skin, the size of my body, and it negates all of that.

Bram Sable-Smith: brams@kff.org, @besables Related Topics Health Care Costs Health Industry Race and Health States Diabetes Florida North Carolina Texas Contact Us Submit a Story Tip

Continue Reading

Technology

CNBC Daily Open: A rough and historically atypical November for U.S. stocks

Published

on

By

CNBC Daily Open: A rough and historically atypical November for U.S. stocks

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., Nov. 26, 2025.

Brendan McDermid | Reuters

The U.S. stock market was closed Thursday stateside for Thanksgiving Day and will reopen on Friday until 1 p.m. ET.

With approximately just 3 hours of trading left for the month, major U.S. indexes are looking to end November in the red, based on CNBC calculations.

As of Wednesday’s close, the S&P 500 was down 0.4% month to date, the Dow Jones Industrial Average 0.29% lower during the same period and the Nasdaq Composite retreating 2.15%, vastly underperforming its siblings as technology stocks stumbled in November.

Unless there’s a huge jump in stocks during the shortened trading session on Friday stateside — which might not be an unequivocally positive move since it would raise more questions about the market’s sustainability — that means the indexes are on track to snap their winning streaks. The S&P 500 and Dow Jones Industrial Average have risen in the past six months, and the Nasdaq Composite seven.

It will also mark a divergence from the historical norm. The S&P 500 has advanced an average of 1.8% in November since 1950, according to the Stock Trader’s Almanac. And in the year following a U.S. presidential election, it typically rises 1.6%.

But it’s not been a typical post-presidential election year. It’s hard to see the market, in the coming months, or even years, moving according to any historical trajectory.

What you need to know today

U.S. futures are mostly flat Thursday night. The stock market was closed during the day for the Thanksgiving break in the U.S. Europe’s Stoxx 600 inched up 0.14%, rebounding from earlier losses.

Alibaba’s AI glasses go on sale. The Quark AI Glasses come in two variants that cost 1,899 Chinese yuan ($268) and 3,799 yuan, less than Meta’s $799 Meta Ray-Ban Display glasses, signaling Alibaba’s competitive entry into the consumer AI market.

Apple files a case against India’s antitrust body. The Competition Commission of India is investigating complaints about Apple’s in-app purchase policies, and could fine the company based on its global turnover — which means a potential $38 billion penalty.

Russia is ready for ‘serious’ discussions for peace. The U.S.-led framework “can be the basis for future agreements,” Russian President Vladimir Putin said Thursday, as translated by Reuters. He added that the U.S. seemed to take Moscow’s position “into account.”

[PRO] Bank of America doesn’t see much upside for 2026. The S&P 500 should rise by a single-digit percentage point, a slowdown from recent years because one supporting factor will be shrinking, said a strategist from the bank.

And finally…

An operator works at the data centre of French company OVHcloud in Roubaix, northern France on April 3, 2025.

Sameer Al-doumy | Afp | Getty Images

Europe’s slow and steady approach to AI could be its edge

It’s unlikely that Europe will lead in building facilities for AI hyperscalers or for the training of AI — that race is considered all but won — but the general consensus is that it could excel in smaller, cloud-focused and connectivity-style facilities.

Europe has “a lot of constraints, but, actually, the more difficult something is to replicate, the more long-term value what you’ve got has,” said Seb Dooley, senior fund manager at Principal Asset Management.

— Tasmin Lockwood

Continue Reading

Sports

Drinkwitz agrees to new 6-year deal with Missouri

Published

on

By

Drinkwitz agrees to new 6-year deal with Missouri

Missouri has agreed to a new six-year contract with coach Eliah Drinkwitz with an average annual compensation of $10.75 million, the school announced Thursday.

Drinkwitz indicated the deal was imminent on social media Thursday morning, thanking the school president, Mun Choi, board of curators, athletic director Laird Veatch, the boosters and fans. “Why stop now!!” he tweeted.

“My family and I believe deeply in the vision and leadership from our administration and are incredibly happy to continue calling Columbia our home,” Drinkwitz said in a statement. “I’m grateful for the unwavering support of President Mun Choi, the Board of Curators, led by Chair Todd Graves and incoming Vice Chair Bob Blitz, along with our athletics director Laird Veatch. We’re also incredibly thankful for the support of our generous donors and NIL partners. I’m committed to continuing our work to build Mizzou into a championship program.”

The move is an aggressive one by Missouri to keep Drinkwitz near the top of the country’s highest-paid coaches, as his base salary will increase to $10.25 million in 2026, which is up from $9 million in 2025.

Drinkwitz received interest from several of the top jobs on the carousel, and the move by the school to agree to a new deal with him is reflective of the trend seen at places like Indiana, SMU and Nebraska in an effort to keep their coaches.

Drinkwitz led Missouri to back-to-back double-digit win seasons in 2023 and 2024, and the program has qualified for its sixth straight bowl game. The Tigers rose to as high as No. 8 in the Associated Press poll in 2023 and No. 6 in 2024. This year, Missouri climbed to No. 14.

During his tenure, Missouri has wins over Ohio State, Iowa, Oklahoma, Tennessee, Florida and LSU. He is 45-28 in six seasons.

Missouri is 7-4, with all four losses coming to teams ranked in the Top 10 at the time.

Continue Reading

Entertainment

Sally Rooney tells court new books may not be published in UK due to Palestine Action ban

Published

on

By

Sally Rooney tells court new books may not be published in UK due to Palestine Action ban

Irish author Sally Rooney has told the High Court she may not be able to publish new books in the UK, and may have to withdraw previous titles from sale, because of the ban on Palestine Action.

The group’s co-founder Huda Ammori is taking legal action against the Home Office over the decision to proscribe Palestine Action under anti-terror laws in July.

The ban made being a member of, or supporting, Palestine Action a criminal offence punishable by up to 14 years in prison.

Rooney was in August warned that she risked committing a terrorist offence after saying she would donate earnings from her books, and the TV adaptations of Normal People and Conversations With Friends, to support Palestine Action.

In a witness statement made public on Thursday, Rooney said the producer of the BBC dramas said they had been advised that they could not send money to her agent if the funds could be used to fund the group, as that would be a crime under anti-terror laws.

Rooney added that it was “unclear” whether any UK company can pay her, stating that if she is prevented from profiting from her work, her income would be “enormously restricted”.

More on Palestine Action

Please use Chrome browser for a more accessible video player

Why was Palestine Action proscribed?

She added: “If I were to write another screenplay, television show or similar creative work, I would not be able to have it produced or distributed by a company based in England and Wales without, expressly or tacitly, accepting that I would not be paid.”

Rooney described how the publication of her books is based on royalties on sales, and that non-payment of royalties would mean she can terminate her contract.

“If, therefore, Faber and Faber Limited are legally prohibited from paying me the royalties I am owed, my existing works may have to be withdrawn from sale and would therefore no longer be available to readers in the UK,” Rooney added, saying this would be “a truly extreme incursion by the state into the realm of artistic expression”.

Rooney added that it is “almost certain” that she cannot publish or produce new work in the UK while the Palestine Action ban remains in force.

She said: “If Palestine Action is still proscribed by the time my next book is due for publication, then that book will be available to readers all over the world and in dozens of languages, but will be unavailable to readers in the United Kingdom simply because no one will be permitted to publish it, unless I am content to give it away for free.”

Sir James Eadie KC, barrister for the Home Office, said in a written submission that the ban’s aim is “stifling organisations concerned in terrorism and for members of the public to face criminal liability for joining or supporting such organisations”.

“That serves to ensure proscribed organisations are deprived of the oxygen of publicity as well as both vocal and financial support,” he continued.

The High Court hearing is due to conclude on 2 December, with a decision expected in writing at a later date.

Continue Reading

Trending